Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose escalation study of FAZ053 alone and with PDR001 in advanced malignancies
jRCT2080223450Phase 1Completed
- Sponsor
- Novartis
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of FAZ053 in Nonhematologic neoplasms, triple-negative breast cancer (TNBC), chordoma and 1 more (2 arms), sponsored by Novartis. Primary endpoints: Maximum tolerated dose and/or recommended phase II dose of FAZ053 (alone and with PDR001) and Safety and tolerability of FAZ053 (alone and with PDR001). Started Feb 2017; status: completed.
02
Drugs
FAZ053
03
Conditions
Nonhematologic neoplasmstriple-negative breast cancer (TNBC)chordomaalveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on jRCT2080223450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223450.